Abstract: Despite significant additions to the HIV prevention toolbox, infection rates across the United States continue to rise among vulnerable adolescents and young adults. Access to these interventions by youth at risk for HIV is limited by the lack of data about their safety and use, compounding the myriad contextual barriers to effectively preventing HIV in this group. The NIH-funded Adolescent Trials Network implemented an innovative approach to the inclusion of adolescents at risk for HIV infection who consented for their own participation in the first adolescent study of HIV preexposure prophylaxis (PrEP). This model of mature minor consent was supported by state-based adolescent treatment statutes that extend an adolescent's ability to consent to participation in research with a sufficient prospect of clinical benefit from the intervention to justify the potential risks, and a balance of benefits and risks that is at least as favorable as available evidence-based alternatives. Important data on the safety and patterns of PrEP use by at-risk adolescents prompted the FDA to revise the label. The expanded indication of PrEP for HIV prevention in adolescents is hoped to inform clinical guidelines and provides a powerful tool to reduce new infections in the United States among vulnerable at-risk adolescents. Lessons learned from this years-long iterative endeavor have implications for improving access to the rapidly evolving landscape of HIV prevention modalities, including recently implemented studies of longacting PrEP formulations designed to reduce the burden of daily adherence required by oral PrEP, a major clinical pitfall for adolescent clinicians and their patients.
BACKGROUND
Despite recent significant additions to the HIV prevention toolbox, infection rates across the United States have continued to rise until recently and remain disproportionately high among adolescent and young adult populations, particularly among sexual and ethnic/racial minorities (Fig. 1) . 1 Tenofovir-emtricitabine is proven efficacious and FDAapproved as pre-exposure prophylaxis (PrEP) for HIV prevention among populations at risk ( Fig. 2) [2] [3] [4] [5] [6] [7] ; however, the risk-benefit ratio of this fixed-dose combination antiretroviral medication may be different in young men and women in whom growing bones may be more vulnerable to tenofovirrelated bone toxicity. 8, 9 Furthermore, some of the normative developmental influences (eg, poor impulse control, inadequate planning, and concomitant mood disorders) [10] [11] [12] that place individuals at risk for HIV infection correlate with behaviors of poor adherence to health care and health seeking behaviors, which diminishes the effectiveness of daily PrEP as an HIV prevention tool (Fig. 3) . 6, 13, 14 In addition, adolescents experience many psychosocial stressors and pressures that contribute to poor self-management skills 15 raising doubts about whether adolescents could adhere to such an intervention long enough to experience a meaningful benefit. However, a pilot study in Chicago of 18-to 22-yearold minority young men who have sex with men demonstrated promise in this prevention intervention for young adults. 16, 17 The need for excellent adherence to PrEP for meaningful protection from HIV infection spurred demonstration projects among adults at risk for infection in the United States. 5, 18 Similarly, an imperative existed for a safety and demonstration project among younger populations of adolescents at risk for infection, so that urgently needed safety and usability data on tenofovir-emtricitabine as PrEP could help facilitate a change in the FDA clinical indication to decrease the age down to age 15 years. 19 Until recently, 20 the FDA approval of tenofovir-emtricitabine for PrEP has been for adults 21 ; however, the lower age limit is not specified in the Centers for Disease Control and Prevention (CDC) Guidance on PrEP use. 22 The ethical, legal, and regulatory challenges to the inclusion of this important population in biomedical HIV prevention research have been delineated well and so have legislative mandates for the inclusion of children in relevant research. 23, 24 Clinical research that is conducted or funded by the Department of Health and Human Services is subject to the US Code of Federal Regulations (CFR) Title 45 Part 46. Clinical research involving an investigational drug or biologic is also regulated under CFR Title 21 Parts 50 and 56. Both regulations provide additional safeguards for research participants who are children, but they have important differences in their rules for informed consent for adolescents. Title 45 Part 46 allows for the possibility of a waiver of parental permission under limited circumstances, 25 whereas Title 21 Part 50 does not include this waiver of parental permission. 26 When both sets of regulations apply, institutional review boards (IRBs) or other similar ethics review panels may require parental permission when they might otherwise waive it. Researchers are then faced with a dilemma given their desire to establish the benefit of and to improve access to PrEP for potential at-risk adolescents. The requirement for parental permission may make it nearly impossible to obtain crucially needed safety data in adolescents for a drug with proven safety and efficacy for preventing HIV in adults, because adolescents at risk for HIV may not be willing to disclose required information about their risk behaviors to their parents. [27] [28] [29] [30] Tenofovir has been used extensively by both adults and children 20 infected by HIV, and it has also been evaluated in a subgroup of uninfected at-risk young adults in a larger trial, in which tenofovir-emtricitabine efficacy for preventing HIV infection was demonstrated. 5, 6 Therefore, there is sufficient prospect of direct benefit to atrisk adolescents to justify exposure to the risks of the research intervention and maximize their access to a safe and effective HIV PrEP drug. Requiring parental permission may push the adolescent population who would most likely benefit from the intervention away from enrolling in the research for fear of inadvertent disclosure to their parents of highly stigmatized risk behaviors and sexual orientation, of further strain on their already poor or tenuous relationships and of unintended untoward consequences. 19 Without the critical inclusion of adolescents in clinical trials, these youths could obtain this medication off-label (or even on the black market) without the benefit of the necessary safety and usability data until recently.
In the only bridging safety and demonstration adolescent PrEP project that has been successfully developed, implemented, fully enrolled, and completed, a cohort of 15-to 17-year-old adolescents at risk for HIV infection consented for their own participation in this critically important study conducted by the NICHD-/NIH-sponsored Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) across major metropolitan areas in the United States. 31 This report provides a case study of an innovative and iterative approach to paving the way for these efforts. This successful foundational work in a dynamic HIV research landscape that is now moving into novel antiretroviral formulations for HIV prevention, such as long-acting agents that may decrease concerns about adherence and raise new issues (eg, acceptability, tolerability, drug metabolism, and interactions), provides an opportunity to highlight the importance of engaging at-risk adolescent minors in biomedical HIV prevention research.
Preparing for Adolescent PrEP Research
Paving the way for adolescent participation in HIV PrEP research began in the summer of 2009 (Fig. 2) , following the results from iPrEx, 6 through a consultation with a variety of stakeholders on "The Inclusion of Adolescents in Biomedical HIV Prevention Research" that took place in Washington, DC. Meeting participants included representatives from academia, the pharmaceutical industry, ethicists, the Food and Drug Administration (FDA), the US National Institutes of Health, advocacy coalitions, clinicians, community members, and adolescents. The published proceedings of this meeting outlined key preparatory steps to be addressed, including engaging key local and national regulatory authorities early in the dialog about the importance of enrolling US male minors aged 15-17 years who are at risk for HIV infection in research on whether an efficacious HIV prevention intervention among adults is effective in youth. 23, [32] [33] [34] [35] [36] [37] [38] [39] The key issue was whether the participation of mature minors in biomedical research could be increased compared with past experience, as long as they could otherwise access sexual and reproductive health services on their own in the local jurisdictions in which the research was being conducted. Over the ensuing year, consultation was obtained from ethicists, the research community, the FDA, and the Office of Human Research Protections (OHRP) at HHS. All those consulted affirmed the position that, as long as locally permissible by laws and regulations on sexual and reproductive health services, such youth at high risk of HIV infection are effectively mature minors and should be able to provide consent for themselves to participate in a study of tenofovir-emtricitabine as PrEP for HIV prevention. As soon as the investigational new drug application was filed with FDA, which included the PrEP protocol developed by the ATN for this group of at-risk adolescents (Project PrEPare), a series of parallel discussions began at all 13 participating ATN sites across the United States between the investigators who would be potentially enrolling adolescent participants and their IRBs. ATN sites used prepared materials from the iterative process of consultations mentioned above, asking whether IRBs would consider review and approval of Project PrEPare. IRBs approved implementation of the protocol at 7 of the 13 sites. A process evaluation with a more detailed description of these crucial discussions and lessons learned has been recently published. 40 In this process, there were several themes that emerged: (1) extensive preparation and iterative educational discussions with IRB officials are critical to the successful understanding of the project; (2) early consultation with institutional officials is important because there is considerable variability in the interpretation of local regulations (and therefore in their reaction to the study), including differing interpretations of state regulations by sites located within the same state; (3) key foundational evidence and guidance should be readily available to address emotional reactions on the part of IRBs (eg, members' perspectives as parents) and, in some cases, from other institutional officials (eg, attorneys) who may be concerned about institutional liability; and (4) structural level changes to address barriers and update local laws and regulations are crucial to more uniformly address the importance of prevention as part of "treatment" for common adolescent conditions, so that application of these regulations to "research" can be more consistent. Addressing these barriers would validate that HIV prevention services are as important as treatment services for youth. Research involving conditions affecting mature minors may be permitted based on the same local laws and regulations, regardless of whether the research is about preventing or treating a disease. Currently, there are inconsistent interpretations where Project PrEPare was not approved. Although studies on the treatment of HIVinfected mature minors are allowed, tenofovir-emtricitabine is accessible for preventive clinical care among at-risk minors and as part of combination antiretroviral therapy for HIVinfected youth (Renata Arrington-Sanders, MD, personal communication, 2015). The clinical availability of preventive treatment for at-risk minors ideally would support the ability of mature minors to consent to participating in research on HIV prevention strategies.
Project PrEPare opened to accrual in the summer of 2013 and concluded enrollment in the fall of 2014 with 78 participants, of whom 47 completed 48 weeks of follow-up by the fall of 2015. 31 It demonstrated that adolescents can successfully participate in an HIV biomedical prevention study and that PrEP can be safely used by at-risk adolescents to prevent HIV infection, when used alongside appropriate adherence support systems to ensure it is taken as prescribed. Additional in-depth analyses on biomedical and behavioral outcomes are ongoing, including on youth's experiences of their study participation. 41 
Oral PrEP is Only the Beginning
An important part of the NICHD mission is to ensure that all children have the chance to achieve their full potential for healthy and productive lives, free from disease or disability. 42 Although the success of developing, enrolling, and completing the first PrEP study in adolescent minors represents an important milestone in the battle to reduce new HIV infections in at-risk populations, high rates of HIV infection among those participants with little to no detectable blood tenofovir level in this study, 31 and in its companion study conducted in older adolescents and young adults (18-22 years of age), 17 are a stark reminder of the obvious-if you don't take it, it doesn't work. Meanwhile, outside of research, the epidemic continues to rise in these young people (Fig. 1) . Furthermore, findings from the ATN study whose participants were adolescents 15-17 years of age 31 and those in the older youth population 43 demonstrate modest but significant TDFassociated bone mineral density losses that are currently the subject of extended safety evaluations. The need to examine the rate and extent of reversibility of these changes after PrEP discontinuation is particularly important because these losses are occurring before the time youth typically attain peak bone mass. However, encouraging findings from small subanalyses among adult participants in 2 large PrEP efficacy studies indicated that similar losses stabilized 8 or were reversible. 44 Results from the ATN analyses have achieved a landmark milestone, prompting the FDA to revise the label and expand the indication for tenofovir-emtricitabine as PrEP to include at-risk adolescents weighing at least 35 kg. 20 More recently, long-acting formulations of injectable antiretroviral medications have emerged as an exciting HIV prevention option that effectively eliminates the need to take daily oral medication. These formulations are currently under intense study in phase II and III trials in adults at risk for HIV infection, but results are not expected for years (NCT02165202; NCT02720094; NCT03164564). This formulation consists of 2 agents that are analogues of the oral non-nucleoside reverse transcriptase inhibitor rilpivirine, and the integrase strand transfer inhibitor, cabotegravir, which is related to the parent drug dolutegravir. These 2 products have a lengthy track record of safe and effective use in treating many adults and some children with HIV infection. In fact, dolutegravir is a recent example of an antiretroviral medication that was approved simultaneously for treatment of HIV infection in adults and children down to age 12 because of early, concurrent studies completed in children. 45, 46 Although there are many questions about the delivery platforms (safety, acceptability, tolerability, etc.) and the pharmacokinetics of these agents that either have been partially answered or are being addressed in current studies, these questions have clear relevance to adolescent populations, which are not likely to be answered through studies in adults. It will be important to include adolescents early in the study of these drugs for HIV prevention, using a model of mature minor consent as locally permissible by laws and regulations, to improve on the tenofovir-emtricitabine experience in which needed safety and effectiveness data to inform FDA labeling for adolescents and young adult at-risk populations have lagged substantially behind adults. This was because the implementation of trials in adolescents was delayed until complete data on safety and efficacy both in treatment and prevention of HIV infection and an FDA label for PrEP among adults were available (Fig.  2) . The rationale behind this staggered, phased-in approach has been widely debated for other potential prevention products, 47, 48 including HIV vaccines and topical microbicide agents, which are far earlier in the drug developmental trajectory (eg, have not been in use among humans for very long) and can potentially add substantial incremental risk to younger populations without yet having sufficient demonstrable prospect of clinical benefit to balance the risk. 49 Thus, if the scientific community is considering earlier inclusion of adolescents in early-phase HIV prevention trials, it seems reasonable to do so for studies of drugs with preliminary evidence (eg, interim analysis) from appropriately designed randomized controlled trials that demonstrate safety and efficacy at preventing HIV infection in at-risk adults, but without necessarily waiting until these data are complete, 49 especially for those drugs for which there is considerable use data in treating adults and children with HIV infection.
Advancing HIV Biomedical Prevention Options for Adolescents
In the background of an increasing HIV epidemic among US young men who have sex with men, coupled with the success of the ATN PrEP study in adolescents aged 15-17 years, an innovative research agenda to improve the quality of the lives of our nation's at-risk adolescents has been encouraged through the ATN. Unfortunately, factors in the syndemic model 50 prove to be formidable and consistent contributors to the rising HIV incidence in young people in the United States. The health care and research community cannot afford to wait before beginning planning to study and obtain data to license these more promising agents for use in young people. Clearly, delaying until there is an accumulation of scientific proof that matches preparatory efforts over 7 years with Truvada ( Fig. 2) is not ideal. Of course, such studies may not require the design of large efficacy trials in youth, only complementary bridging licensure studies (eg, safety, usability, pharmacokinetics/pharmacodynamics, etc.), provided FDA's principle of extrapolation is met: "pediatric effectiveness can be extrapolated from adequate and wellcontrolled studies in adults, usually supplemented with other information obtained in pediatric patients, such as PK studies." 23, 51 Furthermore, the successful approach to informed consent used in the ATN PrEP study could be extended to other contexts in biomedical HIV prevention research among adolescents to advance the development of prevention and treatment strategies, which are important to protect the public health. However, this approach is predicated on at least preliminary evidence of preventive efficacy having been demonstrated in adult studies. Alternatively, when there are data from early-phase studies in adults establishing a sufficient prospect of direct benefit to justify the risks of the intervention, and the pharmacokinetics of the intervention are well-understood, adolescents could be enrolled concurrently with adults in a phase 3 registrational trial to obtain the needed bridging data to support licensure of the product for use in adolescents. When appropriate, adolescents may be included earlier in development, so that a product may be licensed for use in both adolescents and adults at the time of initial marketing approval. 49 Information gleaned from these efforts will not only have applicability to domestic populations, but also to the health of adolescents and youth throughout the world. Given the drug-development pipeline for HIV prevention products, 52 it seems the appropriate time to consider whether we can apply the regulatory approach taken with tenofoviremtricitabine as PrEP for at-risk adolescents aged 15-17 years to newer agents now being actively pursued in adult prevention research. For newer products where a reasonable prospect of direct benefit to the adolescent has been demonstrated (eg, known antiviral efficacy and safety in adults), 23 with the alternative being life-long HIV infection, there could be sufficient basis for allowing at-risk adolescents to consent on their own to participate in such trials as long as local regulations would allow. Similarly, a novel product for which there are no data from HIV-infected populations and for which interim efficacy and safety data from a phase III adult prevention trial are favorable may be considered for testing in adolescents before adult marketing approval, particularly if the adult approval may lead to off-label use in adolescents without crucial safety information. 23 For example, a safety (bridging) study of a novel microbicide agent for intravaginal use in young women, aged 15-17 years, has recently completed enrollment 53, 54 and was the subject of a recent NIH workshop on examining mature minor consent in HIV prevention research. In such cases, rather than adolescents refusing participation to avoid inadvertent disclosure of behaviors, the above approach with adolescent selfconsent, perhaps supplemented with an ombudsman or youth representative who can assist the adolescent in advocating for themselves, might be considered. This approach ensures that at-risk adolescents have the best opportunity to participate, and that the feasibility of trials designed to gather these important data are not threatened. A potential framework for insuring the inclusion of adolescent minor participants in biomedical HIV prevention research is described in Figure 4 . This applies state-based adolescent treatment statutes to extend an adolescent's ability to consent to participation in research with (1) a sufficient prospect of clinical benefit from the intervention to justify the potential risks and (2) the balance of benefits and risks of which is at least as favorable to the adolescent as available evidence-based alternatives (21 CFR 50.52). 49 Subject to local jurisdictional laws and regulations, this approach does not preclude parental involvement but rather encourages it whenever possible. It would also allow increasing levels of adolescent autonomy without compromising necessary protections and is based on the availability of data for a given prevention modality. This framework could substantially yet safely advance the acquisition of critically needed data to inform licensure of biomedical HIV prevention modalities in those who need them most-adolescents who are at risk for HIV infection.
CONCLUSIONS
Although further analysis in Project PrEPare is ongoing, it is important that cutting-edge research aimed to reduce new infections in at-risk adolescents to consider using innovative approaches such as the model of mature minor consent discussed in this report. This approach would include populations who are often neglected and who play a major role in the HIV epidemic as the field continues to evolve rapidly with new agents and platforms becoming available to combat the HIV epidemic. The question is how swiftly the health care and scientific community can work together with ingenuity and flexibility, to adapt and forge pathways that ensure children are appropriately protected and included in this vital research to decisively address what has become a public health emergency.
